Novartis Gets Counterclaims Cut From Heart Drug Patent MDL

By Jasmin Boyce · September 28, 2022, 5:02 PM EDT

A Delaware federal judge has thrown out declaratory judgment counterclaims lodged against Novartis by two generic-drug makers in multidistrict patent litigation over Novartis' heart medication Entresto, determining that the court lacks...

To view the full article, register now.

Documents

Case Information

Case Title

In re: Entresto (Sacubitril/Valsartan) Patent Litigation

Case Number

1:20-md-02930

Court

Delaware

Nature of Suit

Patent - Abbreviated New Drug Application(ANDA)

Date Filed

March 27, 2020